Literature DB >> 27819858

18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.

Esther Mena1, Sara Sheikhbahaei, Mehdi Taghipour, Abhinav K Jha, Esther Vicente, Jennifer Xiao, Rathan M Subramaniam.   

Abstract

OBJECTIVES: We aimed to determine the consistency of quantitative PET measurements of metabolic tumor volume (MTV) and intratumoral heterogeneity index for primary untreated pancreatic adenocarcinomas, when using dual-time point F-FDG PET/CT imaging.
METHODS: This is an institutional review board-approved, retrospective study including 71 patients with pancreatic adenocarcinoma, who underwent dual-time point F-FDG PET/CT imaging, at approximately 1 hour (early) and 2 hours (delayed), after injection. Automated gradient-based and 50% SUVmax-threshold segmentation methods were used to assess the primary tumor MTV and metabolic intratumoral heterogeneity index, calculated as the area under cumulative SUV-volume histograms (AUC-CSH), with lower AUC-CHS indexes corresponding to higher degrees of tumor heterogeneity. We defined that more than a ±10% change in MTV or AUC-CSH, compared with baseline, as clinically significant.
RESULTS: Seventy-one FDG-avid pancreatic tumors were identified, with an average tumor diameter of 3.4 ± 0.9 cm (range, 1.5-6.4 cm). Metabolic tumor volume values remained consistent between early and delayed imaging when using the gradient PET segmentation method (P = 0.086), whereas statistically significant change was seen when using 50% SUVmax-threshold segmentation (P < 0.001). A decrease in more than 10% change in MTV (% ΔMTV) was observed in 70.4% (50/71) tumors, and 7.0% (5/71) of the tumors showed an increase more than 10 % ΔMTV, when using the 50% SUVmax-threshold segmentation. AUC-CSH indexes showed statistically significant differences between early and delayed time points (P < 0.001), when using the gradient segmentation. AUC-CSH index decreased by 10% or greater in 40.8% (29/71) of the tumors. AUC-CSH index remained stable between early and delayed when using the 50% SUVmax-threshold segmentation (P = 0.148) with percentage of change of less than 10% for all tumors.
CONCLUSIONS: Metabolic tumor volume was relatively stable between early and delayed time points when PET gradient segmentation was used but changed greater than 10% in 77.4% of the tumors at delayed time point when threshold segmentation was used. The tumor heterogeneity index (AUC-CSH) changed greater than 10% in 40.8% of tumors at delayed imaging, when gradient segmentation was used but remained stable when threshold segmentation was used. It is important to standardize uptake time and segmentation methods to use FDG PET MTV and heterogeneity index as imaging biomarkers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27819858      PMCID: PMC5360463          DOI: 10.1097/RLU.0000000000001446

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  38 in total

1.  Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET.

Authors:  Jianhua Yan; Jason Lim Chu-Shern; Hoi Yin Loi; Lih Kin Khor; Arvind K Sinha; Swee Tian Quek; Ivan W K Tham; David Townsend
Journal:  J Nucl Med       Date:  2015-07-30       Impact factor: 10.057

2.  Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.

Authors:  Alin Chirindel; Krishna C Alluri; Muhammad A Chaudhry; Richard L Wahl; Timothy M Pawlik; Joseph M Herman; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2015-05       Impact factor: 3.959

3.  Pancreatic resection for M1 pancreatic ductal adenocarcinoma.

Authors:  Shailesh V Shrikhande; Jörg Kleeff; Carolin Reiser; Jürgen Weitz; Ulf Hinz; Irene Esposito; Jan Schmidt; Helmut Friess; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2006-10-25       Impact factor: 5.344

4.  Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.

Authors:  Florent Tixier; Catherine Cheze Le Rest; Mathieu Hatt; Nidal Albarghach; Olivier Pradier; Jean-Philippe Metges; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

5.  Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.

Authors:  Mathieu Hatt; Catherine Cheze-le Rest; Angela van Baardwijk; Philippe Lambin; Olivier Pradier; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-10-11       Impact factor: 10.057

6.  Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?

Authors:  Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau
Journal:  J Nucl Med       Date:  2012-11-30       Impact factor: 10.057

Review 7.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

8.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  Tumor volumes measured from static and dynamic 18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography scan: comparison of different methods using magnetic resonance imaging as the criterion standard.

Authors:  Hanwei Chen; Jinzhao Jiang; Junling Gao; Dan Liu; Jan Axelsson; Minyi Cui; Nan-Jie Gong; Shi-Ting Feng; Liangping Luo; Bingsheng Huang
Journal:  J Comput Assist Tomogr       Date:  2014 Mar-Apr       Impact factor: 1.826

Review 10.  Tumor quantification in clinical positron emission tomography.

Authors:  Bing Bai; James Bading; Peter S Conti
Journal:  Theranostics       Date:  2013-10-07       Impact factor: 11.556

View more
  8 in total

1.  No-gold-standard evaluation of image-acquisition methods using patient data.

Authors:  Abhinav K Jha; Eric Frey
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2017-03-10

2.  Practical no-gold-standard evaluation framework for quantitative imaging methods: application to lesion segmentation in positron emission tomography.

Authors:  Abhinav K Jha; Esther Mena; Brian Caffo; Saeed Ashrafinia; Arman Rahmim; Eric Frey; Rathan M Subramaniam
Journal:  J Med Imaging (Bellingham)       Date:  2017-03-03

3.  High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.

Authors:  Hajime Senjo; Kenji Hirata; Koh Izumiyama; Koichiro Minauchi; Eriko Tsukamoto; Kazuo Itoh; Minoru Kanaya; Akio Mori; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
Journal:  Blood Adv       Date:  2020-05-26

4.  Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy.

Authors:  Hunter C Gits; Amy H Tang; William S Harmsen; William R Bamlet; Rondell P Graham; Gloria M Petersen; Thomas C Smyrk; Amit Mahipal; Roman O Kowalchuk; Jonathan B Ashman; William G Rule; Dawn Owen; Michelle A Neben Wittich; Robert R McWilliams; Thorvardur Halfdanarson; Wen Wee Ma; Terence T Sio; Sean P Cleary; Mark J Truty; Michael G Haddock; Christopher L Hallemeier; Kenneth W Merrell
Journal:  J Gastrointest Oncol       Date:  2021-10

5.  The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.

Authors:  Jun Liu; Yukun Si; Ziang Zhou; Xu Yang; Cuicui Li; Luodan Qian; Li Juan Feng; Mingyu Zhang; Shu Xin Zhang; Jie Liu; Ying Kan; Jianhua Gong; Jigang Yang
Journal:  Cancer Imaging       Date:  2022-07-05       Impact factor: 5.605

6.  The exploration of quantitative intra-tumoral metabolic heterogeneity in dual-time 18F-FDG PET/CT of pancreatic cancer.

Authors:  Guorong Jia; Jian Zhang; Rou Li; Jianhua Yan; Changjing Zuo
Journal:  Abdom Radiol (NY)       Date:  2021-04-18

7.  Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer.

Authors:  Ana María Garcia-Vicente; David Molina; Julián Pérez-Beteta; Mariano Amo-Salas; Alicia Martínez-González; Gloria Bueno; María Jesús Tello-Galán; Ángel Soriano-Castrejón
Journal:  Ann Nucl Med       Date:  2017-09-08       Impact factor: 2.668

8.  A Bayesian approach to tissue-fraction estimation for oncological PET segmentation.

Authors:  Ziping Liu; Joyce C Mhlanga; Richard Laforest; Paul-Robert Derenoncourt; Barry A Siegel; Abhinav K Jha
Journal:  Phys Med Biol       Date:  2021-06-14       Impact factor: 3.609

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.